Targeting bacterial surface structures to fight antibiotic resistance
Official title: Bacteriology Core
Funded at Scripps Research Institute, the · NIH-11082425 · Data updated 2026-11-12
This study is working on creating special antibodies that can help your body fight off tough infections caused by bacteria that don't respond to regular antibiotics, like some strains of Staphylococcus aureus and Neisseria gonorrhoeae, with the hope of offering better treatment options for patients dealing with these stubborn infections.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | May 9, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $223,893 |
| NIH project number | 5P01AI172525-03 |
| Project ID | NIH-11082425 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from infections caused by antibiotic-resistant bacteria, particularly those with severe or recurrent infections.
✕Less likely to help
Patients with infections caused by non-bacterial pathogens or those who do not have antibiotic-resistant infections may not benefit from this research.
What this research studies
This research focuses on developing antibodies that specifically target glycans on the surface of harmful bacteria, such as antibiotic-resistant strains of Staphylococcus aureus and Neisseria gonorrhoeae. By creating these targeted antibodies, the research aims to enhance the body's ability to combat infections caused by these resistant pathogens. The approach includes testing the effectiveness of these antibodies in laboratory assays and in animal models to determine their potential in treating serious bacterial infections. Patients may benefit from new treatment options that could be more effective against antibiotic-resistant infections.
Why it matters
Potential benefit: If successful, this research could lead to new antibody therapies that effectively treat infections caused by antibiotic-resistant bacteria.
How similar studies have gone: Previous research has shown promise in using targeted antibodies to combat bacterial infections, indicating that this approach could be effective.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Horswill, Alexander R — Scripps Research Institute, the
- Study coordinator: Horswill, Alexander R
Related research
Other NIH-funded projects on the same topics.
-
The Participant Center helps people join and stay in a nationwide health study
A nationwide program to support people in joining, contributing biosamples, and staying connected to a large health study in the United States.
-
Data Sharing and Bioinformatics Core for Viral Systems Biology
A center-led effort to manage, share, and interpret large viral systems biology data using open tools and a community-friendly portal.
-
Germline-targeted HIV vaccines using membrane liposome tech to trigger bnAbs
A new HIV vaccine approach aims to spark broadly neutralizing antibodies by showing MPER on membranes, tested in models and early studies to guide future human trials.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
Developing new antivirals for flaviviruses
A research team is working to create oral antiviral drugs targeting flaviviruses to treat infections that affect millions of people.
-
CoV inhibitors targeting non-enzymatic SARS-CoV-2 components
A multicenter research effort seeks antiviral ideas that block SARS-CoV-2 parts that don’t work through traditional enzymes, aiming to help people affected by COVID-19.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.